Mylan NV
Find Ratings Reports
-1.4 |
-3.6%
MYLAN NV's gross profit margin for the fourth quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its industry. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.64 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 19.71% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q4 FY17 | Q4 FY16 |
|---|---|---|
| Net Sales ($mil) | 3238.9 | 3267.8 |
| EBITDA ($mil) | 1084.1 | 1099.7 |
| EBIT ($mil) | 619.7 | 673.0 |
| Net Income ($mil) | 244.3 | 417.5 |
| Balance Sheet | Q4 FY17 | Q4 FY16 |
|---|---|---|
| Cash & Equiv. ($mil) | 480.5 | 1260.2 |
| Total Assets ($mil) | 35806.3 | 34726.2 |
| Total Debt ($mil) | 14661.0 | 15472.6 |
| Equity ($mil) | 13307.6 | 11116.2 |
| Profitability | Q4 FY17 | Q4 FY16 |
|---|---|---|
| Gross Profit Margin | 57.26 | 56.62 |
| EBITDA Margin | 33.47 | 33.65 |
| Operating Margin | 19.13 | 20.59 |
| Sales Turnover | 0.33 | 0.32 |
| Return on Assets | 1.94 | 1.38 |
| Return on Equity | 5.23 | 4.31 |
| Debt | Q4 FY17 | Q4 FY16 |
|---|---|---|
| Current Ratio | 1.13 | 1.49 |
| Debt/Capital | 0.52 | 0.58 |
| Interest Expense | 121.1 | 138.7 |
| Interest Coverage | 5.12 | 4.85 |
| Share Data | Q4 FY17 | Q4 FY16 |
|---|---|---|
| Shares outstanding (mil) | 524.21 | 535.33 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.46 | 0.78 |
| Book value / share | 25.39 | 20.77 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 4759031.0 | 6053074.0 |
HOLD. This stock's P/E ratio indicates a significant discount compared to an average of 100.58 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 24.51. For additional comparison, its price-to-book ratio of 1.61 indicates a significant discount versus the S&P 500 average of 3.18 and a significant discount versus the industry average of 7.30. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYL 31.64 | Peers 100.58 | MYL 10.36 | Peers 16.39 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. MYL is trading at a significant discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. MYL is trading at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| MYL 6.99 | Peers 13.65 | MYL 0.10 | Peers 0.43 | |||||||||||||||||||||
|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. MYL is trading at a significant discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. MYL trades at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| MYL 1.61 | Peers 7.30 | MYL 41.75 | Peers -268.64 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. MYL is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. MYL is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| MYL 1.80 | Peers 24.31 | MYL 7.50 | Peers 17.65 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. MYL is trading at a significant discount to its industry on this measurement. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. MYL significantly trails its peers on the basis of sales growth |
|||||||||||||||||||||||
